Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Fennec Pharmaceuticals Inc

Healthcare US FENC

7.89USD
0.30(3.95%)

Last update at 2026-03-10T20:00:00Z

Day Range

7.528.34
LowHigh

52 Week Range

6.3011.92
LowHigh

Fundamentals

  • Previous Close 7.59
  • Market Cap192.10M
  • Volume111679
  • P/E Ratio175.75
  • Dividend Yield-%
  • EBITDA-13.00900M
  • Revenue TTM44.95M
  • Revenue Per Share TTM1.68
  • Gross Profit TTM 1.45M
  • Diluted EPS TTM0.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -23.71400M -17.34600M -18.10900M -12.77500M -9.88800M
Minority interest - - - - -
Net income -24.83900M -17.45600M -17.92200M -12.46000M -9.88800M
Selling general administrative 17.72M 12.24M 12.95M 7.40M 5.40M
Selling and marketing expenses 2.79M - - - -
Gross profit 1.45M - 0.17M - 0.00000M
Reconciled depreciation - 0.02M 0.40M 0.06M -
Ebit -22.58900M -17.22300M -17.88500M -13.07300M -11.09700M
Ebitda -22.54300M -17.18500M -17.98500M -13.00900M -10.57600M
Depreciation and amortization 0.05M 0.04M -0.10000M 0.06M 0.52M
Non operating income net other - -0.12300M -0.22400M 0.23M 0.52M
Operating income -22.58900M -17.22300M -17.88500M -13.00900M -10.40900M
Other operating expenses 24.12M 17.22M 18.05M 13.01M 10.41M
Interest expense 0.98M 0.13M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 0.20M 0.05M 0.09M 0.25M 0.52M
Net interest income -0.93200M -0.07200M -0.31500M 0.25M 0.35M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.12M 0.11M -0.18700M -0.31500M -0.34800M
Total revenue 1.53M 0.00000M 0.17M 0.00000M 0.00000M
Total operating expenses 24.04M 17.22M 18.05M 13.01M 10.41M
Cost of revenue 0.09M - - - 0.00000M
Total other income expense net -1.12500M -0.12300M -0.22400M 0.23M 0.17M
Discontinued operations - - - - -
Net income from continuing ops -23.71400M -17.34600M -18.10900M -12.77500M -9.88800M
Net income applicable to common shares -23.71400M -17.34600M -18.10900M -12.77500M -9.88800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 26.73M 26.94M 22.41M 31.42M 14.15M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.61M 0.06M 0.25M 0.28M 0.23M
Total liab 38.29M 29.51M 6.64M 2.35M 2.27M
Total stockholder equity -11.56254M -2.56900M 15.77M 29.07M 11.88M
Deferred long term liab - 0.21M 0.03M - 0.26M
Other current liab 3.76M 2.22M 0.88M 0.78M 0.66M
Common stock 143.57M 142.59M 140.80M 140.73M 106.39M
Capital stock 144.31M 142.59M 140.80M 140.73M 106.39M
Retained earnings -218.12328M -203.20000M -179.48600M -162.14000M -144.03100M
Other liab - 0.26M 4.99M - -
Good will - - - - -
Other assets -0.00000M 0.21M 0.03M 1.07M 0.26M
Cash 13.20M 23.77M 21.10M 30.34M 13.65M
Cash and equivalents - - - - -
Total current liabilities 7.51M 4.61M 1.65M 2.35M 2.27M
Current deferred revenue -0.02100M - - - -
Net debt 16.38M 1.12M -16.11200M -30.34400M -13.65000M
Short term debt 0.02M - -0.01200M - -
Short long term debt - - - - -
Short long term debt total 29.58M 24.90M 4.99M - -
Other stockholder equity 61.76M 56.80M 53.21M 49.23M 48.27M
Property plant equipment - - - - -
Total current assets 26.72M 26.73M 22.39M 31.42M 13.88M
Long term investments - - - - -
Net tangible assets - -2.56900M 15.77M 29.07M 11.88M
Short term investments - - - - -
Net receivables 8.77M 1.54M - - -
Long term debt 30.93M 24.90M 4.99M - -
Inventory 2.14M 0.58M - - -
Accounts payable 3.76M 2.39M 0.78M 1.57M 1.61M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.24M 1.24M 1.24M 1.24M 1.24M
Additional paid in capital - - - - -
Common stock total equity - - 140.80M 140.73M 106.39M
Preferred stock total equity - - - - -
Retained earnings total equity - - -179.48600M -162.14000M -144.03100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00597M 0.21M 0.03M - 0.26M
Deferred long term asset charges - - - - -
Non current assets total 0.00597M 0.21M 0.03M 0.00000M 0.26M
Capital lease obligations 0.02M - - - -
Long term debt total - - 4.99M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - - - - 0.00000M
Change to liabilities 1.61M -0.79400M -0.04100M 0.63M 0.16M
Total cashflows from investing activities - - - - -
Net borrowings 20.17M 4.99M 4.99M 4.99M 4.99M
Total cash from financing activities 20.73M 4.98M 32.29M -0.07100M 2.35M
Change to operating activities 1.61M -0.13800M -0.72200M -0.01100M -0.04500M
Net income -23.71400M -17.34600M -18.10900M -12.77500M -9.88800M
Change in cash 2.67M -9.24400M 16.69M -9.13100M -5.47900M
Begin period cash flow 21.10M 30.34M 13.65M 22.78M 28.26M
End period cash flow 23.77M 21.10M 30.34M 13.65M 22.78M
Total cash from operating activities -18.05800M -14.22200M -15.59500M -9.06000M -7.82600M
Issuance of capital stock - 0.00000M 31.97M - 0.00000M
Depreciation 0.13M 0.01M 0.40M 0.06M -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.57600M -0.57600M -0.57600M -0.57600M -
Change to account receivables -1.54500M -1.54500M -1.54500M -1.54500M -
Sale purchase of stock - -0.00800M 32.29M -0.07100M 2.33M
Other cashflows from financing activities 25.73M 4.98M 0.32M -0.07100M 2.35M
Change to netincome 4.40M 4.04M 2.88M 3.08M 1.93M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - -0.21400M -0.43100M -0.06500M -0.02800M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -9.24400M 16.69M -9.13100M -5.47900M
Change in working capital 1.10M -0.93200M -0.76300M 0.57M 0.13M
Stock based compensation 4.09M 3.75M 2.79M 2.67M 1.82M
Other non cash items 0.33M 0.31M 0.49M 0.48M 0.10M
Free cash flow -18.05800M -14.22200M -15.59500M -9.06000M -7.82600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
FENC
Fennec Pharmaceuticals Inc		 0.30 3.95% 7.89 175.75 7.66 4.27 60.74 3.61 24.21
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc

68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709

Key Executives

Name Title Year Born
Mr. Rostislav Raykov CEO & Director 1976
Mr. Robert C. Andrade Chief Financial Officer 1975
Mr. Mark Meier Sr. VP of Commercial NA
Mr. Mark Gowland Controller NA
Mr. Lei Fang Pres of Pharstat Inc NA
Ms. Anne McKay Regulatory Consultant 1954
Mr. Alexander D. Smith M.S. Consultant NA
Mr. Adrian J. Haigh Chief Operating Officer 1959
Mr. Lei Fang President of Pharstat Inc NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.